乳腺癌易感基因研究进展:从突变机制到临床应用
Progress in Breast Cancer Susceptibility Gene Research: From Mutation Mechanisms to Clinical Applications
摘要: 乳腺癌是全球女性发病率最高的恶性肿瘤,其发生与遗传因素紧密相关。近年来,乳腺癌易感基因研究取得显著进展,为疾病的早期筛查、精准诊断和个体化治疗提供了新方向。本文从国内外两方面综述乳腺癌易感基因研究现状。国内研究聚焦于BRCA1/2基因突变的检测、与临床特征的关联及治疗策略探索,同时关注CDCA8、SHC1等其他易感基因的作用;国外研究在BRCA1/2基因突变的机制、临床特征、遗传咨询和靶向治疗等方面更为深入。目前,BRCA1/2基因突变与其他基因变异的交互作用、不同种族人群的突变谱差异等问题有待进一步研究。未来研究应注重多学科合作,整合多组学技术,以实现乳腺癌的精准分型和个体化治疗。
Abstract: Breast cancer is the most prevalent malignant tumor among women worldwide, and its occurrence is closely related to genetic factors. In recent years, significant progress has been made in the research of breast cancer susceptibility genes, providing new directions for early screening, precise diagnosis, and personalized treatment. This paper reviews the current status of research on breast cancer susceptibility genes from both domestic and international perspectives. Domestic research focuses on the detection of BRCA1/2 gene mutations, their association with clinical features, and exploration of treatment strategies, while also paying attention to the role of other susceptibility genes such as CDCA8 and SHC1. International research has delved deeper into the mechanisms of BRCA1/2 gene mutations, clinical characteristics, genetic counseling, and targeted therapy. At present, issues such as the interactions between BRCA1/2 gene mutations and other gene variations, as well as the mutation spectrum differences among different racial groups, remain to be further studied. Future research should emphasize interdisciplinary collaboration and the integration of multi-omics technologies to achieve precise subtyping and personalized treatment of breast cancer.
文章引用:谭远锋, 杨露. 乳腺癌易感基因研究进展:从突变机制到临床应用[J]. 临床医学进展, 2025, 15(7): 1003-1009. https://doi.org/10.12677/acm.2025.1572084

参考文献

[1] 申晓燕. 62例乳腺癌易感基因BRCA1/2突变的高通量测序分析[J]. 深圳中西医结合杂志, 2020, 30(5): 20-21.
[2] 吴楠, 于津浦, 赵晶. 二代测序检测乳腺癌易感基因在乳腺癌发病风险预测及临床治疗中的应用[J]. 中国肿瘤临床, 2017, 44(20): 1024-1028.
[3] 徐晓菲. 应用多重PCR及第二代测序技术建立乳腺癌易感基因(BRCA1/2)突变检测平台[D]: [硕士学位论文]. 北京: 中国人民解放军医学院, 2016.
[4] 张文夏, 杨定华, 王恩礼. 变性高效液相色谱分析技术对乳腺癌易感基因突变位点检测的敏感性和特异性[J]. 中国妇幼保健, 2012, 27(35): 5778-5780.
[5] 吴密璐, 骆玉霜, 韩静绮. 循环肿瘤脱氧核糖核苷酸乳腺癌易感基因1突变指导晚期三阴乳腺癌个体化化疗的研究[Z]. 鉴定日期: 2019-06-28.
[6] 寇利秋, 谢晓露, 陈秀. 奥拉帕利维持治疗乳腺癌易感基因突变铂敏感卵巢癌疗效的Meta分析[J]. 临床药物治疗杂志, 2023, 21(3): 50-55.
[7] 郭亮, 叶婧博, 李慧清. 细胞分裂周期相关蛋白8在肿瘤中作用的研究进展[J]. 右江医学, 2025, 53(4): 367-370.
[8] 郑泽洲, 程端仪, 孙榕, 等. SHC1在肿瘤中增殖、侵袭和迁移相关机制的研究进展[J/OL]. 海南医学院学报, 2025: 1-15. 2025-07-10.[CrossRef
[9] 李华福, 谢群, 叶啸. 乳腺癌易感基因突变对前列腺癌易感性的影响[J]. 现代肿瘤医学, 2018, 26(18): 2910-2917.
[10] 李连心, 张楚微, 肖娟. 乳腺癌易感基因BRCA1/BRCA2的研究进展[J]. 现代医药卫生, 2018, 34(13): 2016-2018.
[11] 程学远, 黄忠. 乳腺癌易感基因突变的研究进展[J]. 广西医学, 2018, 40(20): 2456-2461+2464.
[12] 李苗, 梁星星, 王春梅. 乳腺癌易感基因BRCA1/BRCA2研究发展及乳腺癌的诊断治疗展望[J]. 基因组学与应用生物学, 2017, 36(9): 3648-3654.
[13] 穆坤. 二代测序技术在乳腺癌易感基因胚系突变检测中的应用[D]: [博士学位论文]. 天津: 天津医科大学, 2017.
[14] 郭瑢. 三阴性乳腺癌易感基因突变的筛选与临床评估[D]: [博士学位论文]. 天津: 天津医科大学, 2016.
[15] 雷秋模. 遗传/家族性乳腺癌基因检测(BRCA1/2乳腺癌易感基因检测) [C]//江西省中西医结合学会乳腺专业委员会, 江西省继续教育委员会, 南昌市医学会肿瘤专业委员会. 2015年第七届江西乳腺疾病高层论坛会议资料汇编. 2015: 111-114.
[16] 徐晓菲, 张雯柯, 王莉. 乳腺癌易感基因BRCA1/BRCA2突变的植入前遗传学诊断研究进展[J]. 生殖医学杂志, 2015, 24(6): 504-508.
[17] 邓云特, 王国平. 乳腺癌易感基因1/2的研究进展[J]. 中华乳腺病杂志(电子版), 2013, 7(5): 374-378.
[18] 高润芳. 乳腺癌易感基因突变相关性乳腺癌的治疗及预后[J]. 中国药物与临床, 2013, 13(1): 65-68.
[19] 龚珂, 肖钧方, 刘香婷. 乳腺癌易感基因相关研究现状[J]. 现代肿瘤医学, 2020, 28(23): 4184-4190.
[20] 孙玉树, 赵威, 李孟玮. 心理弹性干预联合对症支持对乳腺癌易感基因突变晚期卵巢癌患者心理弹性及生活质量的影响[J]. 癌症进展, 2024, 22(15): 51671-51675.
[21] 徐梦莉, 赵艳萍, 马焱. 静脉期CT影像组学联合临床特征预测上皮性卵巢癌患者乳腺癌易感基因突变[J/OL]. 中国医学影像技术, 2025: 1-12.
http://kns.cnki.net/kcms/detail/11.1881.R.20250220.0909.002.html, 2025-07-10.
[22] Miki, Y., Swensen, J., Shattuck-Eidens, D., et al. (1994) Astron Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science, 266, 66-71. [Google Scholar] [CrossRef] [PubMed]
[23] Futreal, P.A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., et al. (1994) BRCA1 Mutations in Primary Breast and Ovarian Carcinomas. Science, 266, 120-122. [Google Scholar] [CrossRef] [PubMed]
[24] Pal, T., Permuth-Wey, J., Betts, J.A., et al. (2013) BRCA1 and BRCA2 Mutation Frequencies and Cancer Risk in a Population-Based Study of African American and Hispanic women with Early-Onset Breast Cancer. Journal of Clinical Oncology, 31, 104-110.
[25] Kuchenbaecker, K.B., Hopper, J.L., Barnes, D.R., et al. (2017) Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1and BRCA2 Mutation Carriers. JAMA, 317, 2402-2416. [Google Scholar] [CrossRef] [PubMed]
[26] Robson, M.E., Foulkes, W., Neuhausen, S.L., et al. (2017) American Society of Clinical on Cology Policy Statement: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 35, 562-569.
[27] Fong, P.C., Boss, D.S., Yap, T.A., et al. (2009) Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRC a Mutation Carriers. The New England Journal of Medicine, 361, 123-134. [Google Scholar] [CrossRef
[28] NCCN (2025) Guidelines. Breast Cancer, Version 2.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
[29] Tischkowitz, M. and Hurst, D. (2009) BRCA1 and BRCA2: More than Just Breast and Ovarian Cancer. Journal of Medical Genetics, 46, 76-88.
[30] Lord, C.J. and Ashworth, A. (2016) The Biology of BRCA1 and BRCA2. Nature Reviews Cancer, 16, 118-131. [Google Scholar] [CrossRef] [PubMed]
[31] Lee, M.K., Hu, D.N., Andrews, K.E., et al. (2017) Breast Cancer Risks in Families with BRCA1 or BRCA2 Mutations. JAMA Oncology, 3, 47-53.
[32] Domchek, S.M., Friebel, T.M., Singer, C.F., et al. (2010) Association of BRCA1and BRCA2 Mutations with Survival in Women with Invasive Breast Cancer. JAMA, 303, 1073-1081.
[33] Weitzel, J.N., Cragun, J.M., Berry M.W., et al. (2017) Hereditary Breast Cancer: New Genetic Markers, New Therapies. CA: A Cancer Journal for Clinicians, 67, 134-146.
[34] Tutt, A., Robson, M., Kaufman, B., et al. (2017) Olaparib Tablets as Single Agent in Patients with Advanced BRCA-Mutated HER2-Negative Breast Cancer (OlympiAD): A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial. The Lancet, 389, 240-248.
[35] Kaufman, B., Shapira-Frommer, R., Audeh, M.W., et al. (2015) Olaparib Monotherapy in Patients with Advanced Cancer and a Germline BRCA1 or BRCA2 Mutation. Journal of Clinical Oncology, 33, 141-146. [Google Scholar] [CrossRef
[36] Fong, P.C., Yap, T.A., Boss, D.S., et al. (2012) PARP Inhibitors: Bench to Bedside and Back. Cancer Cell, 21, 11-24.
[37] Murad, T.M., Tutt, A.N., de Azambuja, E., et al. (2018) Homologous Recombination Deficiency and Response to Platinum-Based Chemotherapy in Triple-Negative Breast Cancer: A Retrospective Analysis. The Lancet Oncology, 19, 104-115.
[38] Andresen, Z., Nanda, R., Lin, N.U., et al. (2018) The Evolving Role of PARP Inhibitors in the Treatment of Breast Cancer. Breast Cancer Research, 20, 11.
[39] Dezentje, D.A., van Weerden, W.M., Koster, M.N., et al. (2018) BRCA1and BRCA2 Mutations in Breast Cancer: Implications for Treatment and Prognosis. Breast, 39, 106-113.
[40] Korde, L.A., Theriault, R.L., McShane, L.M., et al. (2015) Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 26, v15-v32.